Slingshot members are tracking this event:
Phase 2 results for MGCD265 (glesatinib) in non-small cell lung cancer
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Mar 16, 2019
Don’t see a project related to the catalyst you care about?
Related Keywords Glesatinib, Mgcd265, Non-small Cell Lung Cancer, Nsclc, Open-label, Phase 2, Met Gene